Systemic Inflammatory Biomarkers in Ovarian Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2024-09-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In cancer patients, prognostic markers are needed to improve the management and clinical course of both the cancer itself and surgery therefor. Elevated systemic inflammatory markers are associated with morbidity and mortality in most cancer types. In this study, the investigators aimed to determine the prognostic value of inflammatory markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) in patients undergoing cytoreductive surgery for ovarian cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer

NCT05927818

Sentinel Lymph Node Ovarian Carcinoma

RECRUITING NA

New Biomarkers Evaluating Ovarian Cancer

NCT01466049

Adnexal Mass

COMPLETED

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

NCT05236686

Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma

RECRUITING NA

Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

NCT00626873

Ovarian Cancer

COMPLETED PHASE1

Tumor Microenvironment in Ovarian Cancer

NCT06272240

Ovarian Cancer Stage III Ovarian Cancer Stage IV

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Major gynaecological cancer surgery is a procedure with high complication rates and mortality risk due to both the patient' s old age and comorbidities and the extent of the surgery. Among such surgeries, ovarian cancer-related surgery has the highest mortality rate. Despite advances in early drug therapy and improvements in the cytotoxicity of drugs, ovarian cancer is frequently diagnosed at advanced stages, which further increases morbidity and mortality rates. Although many years have passed, the prognostic role of cytoreductive surgery on survival in ovarian cancers continues to be important. Predicting postoperative outcomes in these surgeries may reduce the length of hospital stay, need for stay in the intensive care unit, complications, and mortality. Therefore, the role of systemic inflammatory biomarkers needs to be comprehensively investigated to understand the carcinogenic mechanisms better.

For this purpose, the investigators planned to evaluate the prognostic effect of systemic inflammatory biomarkers on postoperative complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients undergoing cytoreduction surgery for ovarian cancer

group with complications

Intervention Type OTHER

Complications in patients undergoing cytoreduction surgery for ovarian cancer

group without complications

Intervention Type OTHER

Complications in patients undergoing cytoreduction surgery for ovarian cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

group with complications

Complications in patients undergoing cytoreduction surgery for ovarian cancer

Intervention Type OTHER

group without complications

Complications in patients undergoing cytoreduction surgery for ovarian cancer

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18 years of age

Exclusion Criteria

* Patients with acute or inflammatory diseases
* Patients with hematological malignancies
* Patients with autoimmune diseases patients who underwent intraoperative hyperchemotherapy (HIPEC)

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No